Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Interest & Investment Income (2022 - 2025)

Moleculin Biotech (MBRX) has 4 years of Interest & Investment Income data on record, last reported at $40000.0 in Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 60.78% year-over-year to $40000.0; the TTM value through Sep 2025 reached $143000.0, down 81.28%, while the annual FY2024 figure was $550000.0, 59.8% down from the prior year.
  • Interest & Investment Income reached $40000.0 in Q3 2025 per MBRX's latest filing, up from $26000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $392000.0 in Q1 2023 and bottomed at $26000.0 in Q2 2025.
  • Average Interest & Investment Income over 4 years is $150133.3, with a median of $102000.0 recorded in 2024.
  • Peak YoY movement for Interest & Investment Income: surged 926.32% in 2023, then crashed 87.55% in 2025.
  • A 4-year view of Interest & Investment Income shows it stood at $126000.0 in 2022, then surged by 107.94% to $262000.0 in 2023, then tumbled by 82.06% to $47000.0 in 2024, then decreased by 14.89% to $40000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $40000.0 in Q3 2025, $26000.0 in Q2 2025, and $30000.0 in Q1 2025.